Hemophilia Treatment Market – Global Outlook & Forecast 2021-2031

Hemophilia Treatment Market by Disorder Type [Hemophilia A and Hemophilia B], Treatment [On-demand and Prophylaxis], Therapy Type [Immune Tolerance Induction (ITI) Therapy, Replacement Therapy and Gene Therapy] – Global Analysis & Forecast 2021-2031

Clairvoyance Research conducted an in-depth market analysis study of the global hemophilia treatment market. According to the study, the market was valued at ~US$ 12.93 billion in 2020. The market is expected to witness a CAGR of ~6.0% from 2021 to 2031. 

Rising prevalence of hemophilia, increasing investment for R&D activities to launch more effective therapies, rising adoption for prophylaxis treatment and growing government initiatives are some of the pivotal factors propelling the growth of the hemophilia treatment market. However, high cost of treatment is likely to hinder the growth of the market to a certain extent.

With an aim to fast-track the development of hemophilia treatment and to meet the needs of the healthcare sector, several initiatives such as providing necessary funding, grants, permissions, clearances & approvals have been instigated by various organizations and government agencies across the world. For instance, in Feb 2021, The US Food and Drug Administration (FDA) granted Fast Track Designation (FTD) for efanesoctocog alfa, previously known as BIVV001 (rFVIIIFc-VWF-XTEN), in patients with hemophilia A. Efanesoctocog alfa, a novel and investigational factor VIII therapy independent of von Willebrand Factor, is designed to provide near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen.

Hemophilia is a blood disorder that is usually genetically inherited from parents. People born with hemophilia have little or no clotting factor – a protein needed for normal blood clotting. Hemophilia A affects about 1 in every 4,000–5,000 males worldwide, whereas, hemophilia B, is estimated to affect 1 in every 20,000 men. Hemophilia C, is a much rarer form of the disease, is estimated to occur in about 1 case per 100,000 people in the U.S. Each year, around 400 babies are born with some type of hemophilia in the U.S., and it is estimated that there are around 20,000 people living with the disease in the country, most of whom have a severe form of the disease. Therefore, growing prevalence of hemophilia is expected to boost the growth of the hemophilia market.

Government bodies and organizations all across the globe are implementing several initiatives such as conducting educational programs to spread the awareness about hemophilia, its diagnosis, possible treatment and disease management. For instance, in Oct 2020, The International Society on Thrombosis and Haemostasis (ISTH) and the European Association for Hemophilia and Allied Disorders (EAHAD) announced an educational partnership to collaborate on components of the ISTH Gene Therapy in Hemophilia Education Initiative. Together, the ISTH and EAHAD will work with The France Foundation (TFF) to develop and distribute tailored educational materials for the primarily European hemophilia practice community, including: a survey for allied health professionals, train-the-trainer workshops, podcast episodes, an EAHAD 2021 conference briefing and other learning sessions.

However, high cost of the treatment may hamper the growth of market to a certain extent. Hemophilia can be successfully treated but the management of hemophilia is associated with a wide variety of direct and indirect costs, which includes clinic visits, hospitalizations, frequent lab tests, and antihemophilic medications. The average cost of drug therapy for a person with hemophilia can be several hundred thousand dollars per year and annual treatment costs more than $1 million.

The Asia Pacific region is expected to be the fastest growing hemophilia treatment market. Factors such as developing healthcare infrastructure, increasing R&D activities and rising awareness for early diagnosis of the disorder can be attributed to the growth of the region. Countries such as India, China, Japan in the APAC region, are projected to offer significant growth opportunities owing to growing prevalence of hemophilia, rising government initiatives and advancements in the treatment.

The hemophilia treatment market is marked by presence of prominent players such Takeda Pharmaceutical Company Limited, Sanofi, Bayer AG, Pfizer Inc., Baxter, Octapharma AG, Kedrion S.p.A, Grifols, S.A., CSL and Novo Nordisk A/S. Other players operating in the market are Swedish Orphan Biovitrum AB, Genentech, Inc., BioMarin, among others.

About Us

Clairvoyance Research is a leading market research and consulting firm, based out in Kolkata, India. Our research solutions are structured around the following verticals: Healthcare (Medical Devices, Biotechnology, Healthcare IT, Pharmaceuticals, and Others), Food & Beverage, Consumer Goods, Automotive & Transportation, Chemicals & Materials & Others.

Our main offerings are syndicate reports and consulting assignments – We track a number of verticals and strategically publish syndicate reports on topics that have traction in the market. Over the years, we have developed a forte in executing consulting assignments – Clairvoyance Research has been a trusted partner to over 300 global organizations including Fortune 500 companies. We partner with clients from across the globe to identify their highest-value opportunities, address their most critical challenges, and transform their enterprises. We have a rich pool of clientele spanning leading medical device/biotechnology/healthcare IT/pharmaceutical companies, IT/FMCG/automotive/food & beverage companies, consulting companies, private equity firms, venture capitalists, investment banks, government bodies, academic/research institutes, and universities.

We internally house one of the best talents in the industry – Industry Veterans [Subject Matter Experts (SMEs), Key Opinion Leaders (KOLs)] from different verticals with a profound experience of several decades are there on our panel. At each stage of the study, these experts add value to our reports and consulting assignments. We nurture crème de la crème resources; our analysts/consultants come from robust educational backgrounds. The rich pool of experts and analysts/consultants at Clairvoyance Research ensures that the final research study is accurate, universally accepted, and of the highest quality.

 

Contact Us

sales@clairvoyanceresearch.com

Website: www.clairvoyanceresearch.com

Latest Reports

Popular Reports

Summer 3E,Purti Season,22 Buroshibtalla Main Road, Near Leela Petrol Pump, Kolkata, West Bengal-700038
+ 91 8761988338
10 AM to 10 PM
info@clairvoyanceresearch.com
Support line
TOP